Opinion|Videos|July 9, 2024
Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD
Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD), explore the potential of combination therapy, and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes.
Advertisement
Episodes in this series
- When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
- How do treatment options differ in terms of administration schedule (continuous versus non-continuous), and how does the need for breakthrough topical steroids influence your decision on therapy options?
- In the managed care space, what is the role of combination therapy in AD and what restrictions might be considered?
- From a payer’s perspective, how do you take into account when a product does not need continuous use and still be efficacious, potentially allowing for time off therapy?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
5